This is a preview of subscription content, log in via an institution to check access.
Reference
Alrasheed M, et al. Cost-Effectiveness of New Regimens to TREAT Endocarditis in IV Drug Users - Vancomycin VS Dalbavancin VS Oritavancin. 26th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PIN9, 17 May 2021. Available from: URL: https://www.ispor.org/heor-resources/presentations-database/presentation/intl2021-3340/111308
Rights and permissions
About this article
Cite this article
Dalbavancin, oritavancin preferred options for treating infective endocarditis in persons who inject drugs. PharmacoEcon Outcomes News 880, 9 (2021). https://doi.org/10.1007/s40274-021-7767-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-7767-z